FAM193A (family with sequence similarity 193 member A) is a positive regulator of p53 tumor suppressor activity that functions through interaction with p53 repressor proteins. Mechanistically, FAM193A interacts directly with MDM4 and destabilizes it, leading to enhanced p53 transcriptional activity and preventing p53 inactivation 1. FAM193A expression correlates with cellular sensitivity to MDM2/4 inhibitors like Nutlin across diverse cancer cell lines, and CRISPR screening confirmed FAM193A is necessary for optimal response to these therapeutic agents 1. Higher FAM193A expression associates with better prognosis across multiple malignancies 1, and recent genomic studies identified FAM193A mutations as part of a recurrence-predictive model in stage II/III colorectal cancer patients 2. Beyond oncology, rare FAM193A variants have been identified in patients with non-syndromic oral clefts with vertical transmission, suggesting potential developmental roles 3, and genetic variants show association with bisphosphonate-induced osteonecrosis of the jaw in osteoporosis patients 4. While FAM193A's primary characterized function centers on p53 pathway regulation with clear implications for cancer biology and therapy response, its broader biological roles remain incompletely understood.